Cardiff Oncology to Present at Upcoming Investor Conferences in May
Provided By GlobeNewswire
Last update: May 13, 2024
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024.
Read more at globenewswire.com
